Corona Remedies Ltd vs Novartis India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 17, 2026

Key Highlights

The Latest Trading Price of Corona Remedies Ltd is ₹ 1580 as of 19 Feb 10:41 . The P/E Ratio of Corona Remedies Ltd is 0 as of March 2023 .The P/E Ratio of Novartis India Ltd is 0 as of March 2023 . The Market Cap of Corona Remedies Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Novartis India Ltd is ₹ 0 crore as of March 2023 . The revenue of Corona Remedies Ltd for the Mar '26 is ₹ 357.48 crore as compare to the Dec '25 revenue of ₹ 344.68 crore. This represent the growth of 3.71% The revenue of Novartis India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Corona Remedies Ltd for the Mar '26 is ₹ 66.41 crore as compare to the Dec '25 ebitda of ₹ 66.32 crore. This represent the growth of 0.14% The ebitda of Novartis India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Corona Remedies Ltd changed from ₹ 29.95 crore to ₹ 45.33 crore over 8 quarters. This represents a CAGR of 23.03% The net profit of Novartis India Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Corona Remedies Ltd changed from 20 % on March 2023 to 30 % on March 2025 . This represents a CAGR of 14.47% over 3 yearsThe Dividend Payout of Novartis India Ltd changed from 118.09 % on March 2021 to 61.15 % on March 2025 . This represents a CAGR of -12.33% over 5 years .

About Corona Remedies Ltd

Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited', a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli.
Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited'.
A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024. The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat).
The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. In 2004, Company launched the first division, and later named it as Pioneer' division in year 2010; launched Xemx (multispeciality) division in 2005.

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

FAQs for the comparison of Corona Remedies Ltd and Novartis India Ltd

Which company has a larger market capitalization, Corona Remedies Ltd or Novartis India Ltd?

Market cap of Corona Remedies Ltd is 10,880 Cr while Market cap of Novartis India Ltd is 2,984 Cr

What are the key factors driving the stock performance of Corona Remedies Ltd and Novartis India Ltd?

The stock performance of Corona Remedies Ltd and Novartis India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Corona Remedies Ltd and Novartis India Ltd?

As of May 17, 2026, the Corona Remedies Ltd stock price is INR ₹1779.1. On the other hand, Novartis India Ltd stock price is INR ₹1208.8.

How do dividend payouts of Corona Remedies Ltd and Novartis India Ltd compare?

To compare the dividend payouts of Corona Remedies Ltd and Novartis India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.